eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | retinal vein occlusion |
| Comorbidity | |macular edema |
| Sentences | 176 |
| PubMedID- 21494891 | Introduction: the ozurdex((r)) (allergan inc., irvine, ca, usa) dexamethasone drug delivery system (dds) was recently developed as a biodegradable intravitreal implant to provide sustained delivery of 700 mug of preservativefree dexamethasone to the retina and vitreous, and is approved by the united states food and drug administration (fda) for the treatment of macular edema associated with retinal vein occlusion, as well as for noninfectious posterior uveitis. |
| PubMedID- 20148661 | Intravitreal bevacizumab (avastin) in the treatment of macular edema associated with perfused retinal vein occlusion. |
| PubMedID- 21845030 | Grid photocoagulation combined with intravitreal bevacizumab for recurrent macular edema associated with retinal vein occlusion. |
| PubMedID- 23690676 | Unilateral macular edema with central retinal vein occlusion in systemic lupus erythematosus: a case report. |
| PubMedID- 20182882 | Intravitreal triamcinolone acetonide versus bevacizumab therapy for macular edema associated with branch retinal vein occlusion. |
| PubMedID- 24332373 | Study population: thirteen eyes of 13 treatment-naive patients undergoing serial intravitreal anti-vascular endothelial growth factor (vegf) injections for exudative age-related macular degeneration or macular edema attributable to retinal vein occlusion. |
| PubMedID- 24447389 | Additional sources of data included clinical study reports for ranibizumab [27-31], the dexamethasone ivt manufacturer’s submission to the national institute for health and clinical excellence (nice) for dexamethasone ivt and the evidence review group response [32,33] and results of the global evaluation of implantable dexamethasone in retinal vein occlusion with macular edema (geneva) studies reported within the clinicaltrials.gov records [34,35]. |
| PubMedID- 26335912 | Purpose: our aim was to investigate predictive factors associated with efficacy and recurrence after intravitreal bevacizumab (ivb) therapy for macular edema (me) in patients with branch retinal vein occlusion (brvo). |
| PubMedID- 26109021 | Early results of dexamethasone implant, ranibizumab, and triamcinolone in macular edema due to branch retinal vein occlusion. |
| PubMedID- 22824618 | A comparative study between intravitreal triamcinolone and bevacizumab for macular edema due to central retinal vein occlusion with poor vision. |
| PubMedID- 21726846 | Soluble vascular endothelial growth factor receptor-2 and inflammatory factors in macular edema with branch retinal vein occlusion. |
| PubMedID- 22105941 | To investigate whether vitreous fluid levels of vascular endothelial growth factor (vegf), pigment epithelium-derived factor (pedf), and soluble intercellular adhesion molecule 1 (sicam-1) influence visual prognosis and macular edema in patients with central retinal vein occlusion (crvo). |
| PubMedID- 21211297 | Objective: to study the correlation of visual acuity and photoreceptor in eyes with persistent cystoid macular edema associated with branch retinal vein occlusion (brvo). |
| PubMedID- 26501219 | The primary treatment against macular edema with retinal vein occlusion (rvo) has changed from observation in central rvo (crvo) and laser photocoagulation in branch rvo (brvo) to administration of intravitreal agents based on anti-vascular endothelial growth factor (vegf) or anti-inflammatory strategies. |
| PubMedID- 23160823 | The objective of this study is to evaluate functional and morphological changes of the macula after pars plana vitrectomy (ppv) for macular edema with branch retinal vein occlusion (brvo). |
| PubMedID- 26337664 | Two or more dexamethasone intravitreal implants in treatment-naive patients with macular edema due to retinal vein occlusion: subgroup analysis of a retrospective chart review study. |
| PubMedID- 24875368 | Purpose: the aim of this study is to evaluate the long-term efficacy of intravitreal bevacizumab (ivb) in macular edema (me) due to branch retinal vein occlusion (brvo) in a real clinical practice setting at a tertiary referral center. |
| PubMedID- 24600201 | Background: the purpose of this study was to evaluate visual outcomes of arteriovenous sheathotomy for macular edema due to branch retinal vein occlusion (brvo). |
| PubMedID- 23598674 | Twelve-month experience with ozurdex for the treatment of macular edema associated with retinal vein occlusion. |
| PubMedID- 26133058 | Purpose: to evaluate the efficacy and safety of dexamethasone (dex) intravitreal implant for the treatment of macular edema due to branch retinal vein occlusion. |
| PubMedID- 24884703 | Role of inflammation in previously untreated macular edema with branch retinal vein occlusion. |
| PubMedID- 21845032 | It may be most appropriate for motivated, phakic, or pseudophakic patients with simple branch retinal vein occlusions associated with macular edema and significant hemorrhage, who are unwilling or unable to tolerate more frequent intravitreal injections required for anti-vegf therapy, or for patients who have demonstrated intolerance or recalcitrant edema following anti-vegf therapy. |
| PubMedID- 26117932 | The paper presents the first results concerning the aflibercept (eylea) treatment, the last antivegf approved for treatment of the age related macular degeneration (amd), neovascular form and for macular edema due to the central retinal vein occlusion. |
| PubMedID- 25300393 | Purpose: to evaluate the early effects of the intravitreal erodible dexamethasone implant ozurdex in patients with macular edema due to retinal vein occlusion (rvo). |
| PubMedID- 21734622 | Measurement of retinal sensitivity may be useful for assessing branch retinal vein occlusion patients with macular edema. |
| PubMedID- 23883532 | Pars plana vitrectomy with multiple transvenous chorioretinotomies for macular edema due to retinal vein occlusion. |